IP Library Granted Patent US 8,709,739
Granted Patent B2
US 8,709,739 · App. 13/619,241 · Granted Apr 29, 2014

System and method for measuring an analyte in a sample

Inventors: Ronald C. Chatelier (Bayswater, AU); Alastair McIndoe Hodges (Blackburn South, AU); Santhanagopalan Nandagopalan (San Jose, CA)
Assignee: LifeScan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,709,739
App. No.
13/619,241
Filed
Sep 14, 2012
Granted
Apr 29, 2014
Kind
B2
Examiner
BALL, JOHN C
Art Unit
1759
USPC
435/140
Abstract

Methods of determining a corrected analyte concentration in view of some error source are provided herein. The methods can be utilized for the determination of various analytes and/or various sources of error. In one example, the method can be configured to determine a corrected glucose concentration in view of an extreme level of hematocrit found within the sample. In other embodiments, methods are provided for identifying various system errors and/or defects. For example, such errors can include partial-fill or double-fill situations, high track resistance, and/or sample leakage. Systems are also provided for determining a corrected analyte concentration and/or detecting some system error.

Claims (35)

1. A system for determining a corrected glucose concentration of a sample, comprising:

an electrochemical cell having at least two electrodes including a first electrode and a second electrode, the electrochemical cell being sized and configured to receive the sample, the electrochemical cell further configured to determine an initial glucose concentration and also configured to generate a pre-determined voltage between the first and second electrodes for a pre-determined amount of time, and further configured to measure at least one resulting current of the sample during the pre-determined time; and

a processor programmed for receiving a set of data from the electrochemical cell, the data including the initial glucose concentration, at least one applied voltage, and at least one resulting current, the processor further programmed to utilize this data to determine a corrected glucose concentration, said electrochemical cell being further configured to measure a hematocrit level of the sample, and in which the processor receives and utilizes the measured hematocrit level to determine a correction term based on the measured hematocrit level and the initial glucose concentration, the processor being further programmed to utilize the correction term as data in determining the corrected glucose concentration.

2. The system of claim 1 , wherein the processor utilizes a set of equations to determine the correction term depending on the measured hematocrit level and the initial glucose concentration.

3. The system of claim 2 , wherein an equation of the set of equations utilized by the processor is selected to calculate the corrected glucose concentration based on at least one of: a comparison of the measured hematocrit level to one or more predetermined hematocrit levels and a comparison of the initial glucose concentration to one or more predetermined glucose concentration levels.

4. The system of claim 2 , wherein the processor is programmed to calculate the correction term Corr using a first function, the first function being utilized if the hematocrit level H is less than a lower predetermined hematocrit level H L and if the initial glucose concentration G 1 is less than an upper predetermined glucose concentration value G U .

5. The system of claim 4 , wherein the first function is one of the set of equations, the equation being

Corr= K 1 ( H L −H ) G 1

where Corr is the correction value, K 1 is a first constant, H L is the lower predetermined hematocrit level, H is the hematocrit level, and G 1 is the initial glucose concentration.

6. The system of claim 5 , wherein the corrected glucose concentration G 2 is determined by the equation G 2 =G 1 +Corr if the initial glucose concentration G 1 is less than a glucose threshold.

7. The system of claim 5 , wherein the corrected glucose concentration G 2 is determined by the equation

G

2

=

G

1

(

1

+

Corr

100

)

if the initial glucose concentration G 1 is greater than a glucose threshold.

8. The system of claim 2 , wherein the processor is programmed to calculate the correction value Corr using a second function, the second function being utilized if the hematocrit level H is less than a lower predetermined hematocrit level H L and if the initial glucose concentration G 1 is greater than an upper predetermined glucose concentration value G U .

9. The system of claim 8 , wherein the second function is one of the set of equations, the equation being

Corr= K 2 ( H L −H )( G max −G 1 )

where Corr is the correction value, K 2 is a second constant, H L is the lower predetermined hematocrit level, H is the hematocrit level, G max is a predetermined maximum glucose concentration, and G 1 is the initial glucose concentration.

10. The system of claim 1 , wherein the corrected glucose concentration G 2 is determined to be substantially equal to the initial glucose concentration G 1 if the hematocrit level H is greater than an upper predetermined hematocrit level H U and if the first glucose concentration G 1 is less than a lower predetermined glucose concentration G L .

11. The system of claim 2 , wherein the processor is programmed to calculate the correction value Corr using a utilized third function if the measured hematocrit level H is greater than an upper predetermined hematocrit level H U and if the initial glucose concentration G 1 is greater than the lower predetermined glucose concentration G L .

12. The system of claim 11 , wherein the third function is one of the set of equations, the equation being

Corr= K 4 ( H−H U )( G 1 −G L )

where Corr is the correction value, K 4 is a fourth constant, H is the hematocrit level, H U is the upper predetermined hematocrit level, G 1 is the initial glucose concentration, and G L is the lower predetermined glucose concentration.

13. The system of claim 1 , wherein the hematocrit level H is based on at least one resulting current determined during a first time interval T 1 and a second time interval T 2 .

14. The system of claim 1 , wherein the first electrode and the second electrode have an opposing face arrangement.

Assignments (18)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2026
From: LIFESCAN GLOBAL CORPORATION; LIFESCAN CHINA, LLC; LIFESCAN IP HOLDINGS, LLC
To: LIFESCAN ENTERPRISES LLC
Reel/Frame 075848/0012 →
RELEASE OF SECURITY INTEREST Recorded Dec 8, 2025
From: ANKURA TRUST COMPANY, LLC
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 073929/0495 →
RELEASE OF SECURITY INTEREST Recorded Dec 8, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 073929/0316 →
SECURITY INTEREST Recorded Dec 8, 2025
From: LIFESCAN ENTERPRISES LLC
To: ACQUIOM AGENCY SERVICES LLC, AS COLLATERAL AGENT
Reel/Frame 073890/0305 →
RELEASE OF SECURITY INTEREST Recorded Dec 8, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSBWILMINGTON SAVINGS FUND SOCIETY, FSB
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 073928/0626 →
SECURITY AGREEMENT Recorded Dec 8, 2025
From: LIFESCAN ENTERPRISES LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 073893/0622 →
ASSIGNMENT OF PATENT SECURITY INTERESTS (1ST LIEN) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SUCCESSOR AGENT
Reel/Frame 072567/0482 →
TRANSFER OF SECURITY AGREEMENT RECORDED AT REEL 063740, FRAME 0080 Recorded Nov 12, 2024
From: BANK OF AMERICA, N.A., AS RESIGNING AGENT
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SUCCESSOR AGENT
Reel/Frame 069340/0243 →
TRANSFER OF SECURITY AGREEMENT RECORDED AT REEL 047179, FRAME 0150 Recorded Nov 11, 2024
From: BANK OF AMERICA, N.A., AS RESIGNING AGENT
To: ANKURA TRUST COMPANY, LLC, AS SUCCESSOR AGENT
Reel/Frame 069314/0022 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY LIST BY ADDING PATENTS 6990849;7169116; 7351770;7462265;7468125; 7572356;8093903; 8486245;8066866;AND DELETE 10881560. PREVIOUSLY RECORDED ON REEL 050836 FRAME 0737. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 28, 2023
From: LIFESCAN INC.
To: CILAG GMBH INTERNATIONAL
Reel/Frame 064782/0443 →
RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836 Recorded Jun 28, 2023
From: BANK OF AMERICA, N.A.
To: LIFESCAN IP HOLDINGS, LLC; JANSSEN BIOTECH, INC.; JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 064206/0176 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded May 23, 2023
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 063740/0080 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded May 22, 2023
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 063712/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: CILAG GMBH INTERNATIONAL
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 050837/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: LIFESCAN INC.
To: CILAG GMBH INTERNATIONAL
Reel/Frame 050836/0737 →
SECURITY AGREEMENT Recorded Oct 3, 2018
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047186/0836 →
SECURITY AGREEMENT Recorded Oct 2, 2018
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047179/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2017
From: CHATELIER, RONALD C.; HODGES, ALASTAIR MCINDOE; NANDAGOPALAN, SANTHANAGOPALAN
To: LIFESCAN, INC.
Reel/Frame 042924/0150 →
Continuity (3)
Division 12349017 · Jan 6, 2009
Provisional Application 61021713 · Jan 17, 2008
Related Publication 20130098763A1 · Apr 25, 2013